Can new drugs make obesity a medical — not moral — condition?

The drugs, called incretins, not only show powerful results, but may help us reframe obesity.

An injectable drug, already FDA approved to treat type 2 diabetes, has shown promising results in multiple clinical trials as a treatment for obesity.

And, as the New York Times’ Gina Kolata reports, researchers and doctors are hoping that this class of drug, called incretins, will not only prove a potent weapon against obesity, but help people consider the condition a medical — not moral — issue.

“I think this truly gives us a very powerful tool to treat obesity as a disease,” Timothy Garvey, co-author of one of the studies and a professor in the Department of Nutrition Sciences at the University of Alabama at Birmingham, said in a statement.

What are incretins? Incretins are a class of hormones that play a role in your metabolism, particularly when it comes to glucose levels. They’re the basis for semaglutide, a weekly, injectable type 2 diabetes treatment made by Novo Nordisk (sold under the brand name Ozempic). 

The Danish multinational is looking to move semaglutide into the obesity medication market, a veritable pharmaceutical graveyard — one in which they already have a headstone, as FiercePharma points out, with a previous obesity drug failure.

But multiple studies, released in February in the New England Journal of Medicine and JAMA, have results that are getting experts excited. 

“No other drug has come close to producing this level of weight loss — this really is a game-changer,” Rachel Batterham, professor of obesity, diabetes, and endocrinology at University College London and co-author of the NEJM study, said in a statement.

A dramatic drop: Patients in the NEJM study lost, on average, nearly 15% of their body weight, compared to 2.4% in the control group; those in the JAMA study lost a mean of 16%, compared to less than 6% for the control.

Such results are second only to bariatric surgeries, which are the most effective obesity treatment right now, with patients losing 25-30% of their body weight on average, obesity researcher Louis Aronne previously told Kolata.

Surgeries are invasive, however, and never without risk, permanently altering the digestive system; only about 1% of people who qualify for the procedures go through with them, Kolata reports.

A drug (even one that has to be injected) could help a lot more people struggling to lose weight.

But as FiercePharma notes, the incretins trials do have some caveats; the drug can cause gastrointestinal distress, and the studies were too short to judge effectiveness over the long term — and obesity is a chronic condition.

A less judgmental paradigm? In addition to having a potential new treatment option, some experts are hopeful that incretins may help frame obesity as a medical condition in the public’s mind, rather than as a moral failing.

Northwestern obesity researcher and clinician Robert F. Kushner told Kolata that his patients have often been conditioned to see their weight as their fault, that diet and exercise are all that is needed — and for those to fail is an indictment of them.

“I tell them this is a chronic ongoing medical problem, just like diabetes,” Kushner said. He draws a comparison to alcohol and drug addiction, which have moved more firmly from moral failing to medical condition.

Columbia University researcher Rudolph L. Leibel is less hopeful, however. “My guess is that bias will persist and might even be exacerbated by the availability of ‘an easy way out,'” he told Kolata.

Marleen Greenleaf, who was part of an incretins trial, lost 40 pounds and gained a new perspective; the drug immediately dissipated her urge to eat, she told Kolata, and allowed her to believe that the weight is “not her fault.” 

We’d love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [email protected]

Lung cancer drug slashes patients’ risk of death by 51%
Osimertinib, an FDA-approved lung cancer drug, slashes the risk of death for certain patients by 51%, according to new trial results.
The placenta may play a role in the genetic risk of schizophrenia
Researchers at Johns Hopkins have found that genes associated with schizophrenia risk may impact the placenta, not just the brain.
Gain-of-function research is more than just tweaking risky viruses
Gain-of-function experiments in the lab can help researchers get ahead of viruses naturally gaining the ability to infect people in the wild.
The radical drop in maternal mortality was a public health miracle
In 1758 in Sweden, 1205 mothers died for every 100,000 live births, which was likely representative of the global maternal mortality rate.
Chronic pain can be objectively measured using brain signals
Even though pain is universal and we know it happens in the brain, we’ve never before had a way to objectively measure its intensity.
Up Next
synthetic biology
Subscribe to Freethink for more great stories